• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Passage Bio Inc.

    11/14/24 12:03:11 PM ET
    $PASG
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PASG alert in real time by email
    SC 13G 1 p24-3217sc13g.htm PASSAGE BIO, INC.

     

    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
     
    Under the Securities Exchange Act of 1934
     
    (Amendment No.  )*
     

     

    Passage BIO, Inc.

    (Name of Issuer)
     

    Common stock, par value $0.0001 per share

    (Title of Class of Securities)
     

    702712100

    (CUSIP Number)
     

    September 30, 2024

    (Date of event which requires filing of this statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule 13G is filed:
     
    x Rule 13d-1(b)
    ¨ Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 7 Pages)

     

    ______________________________

    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 70271210013GPage 2 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Vestal Point Capital, LP

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    6,100,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    6,100,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,100,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%

    12

    TYPE OF REPORTING PERSON

    IA, PN

             

     

    CUSIP No. 70271210013GPage 3 of 7 Pages

     

    1

    NAMES OF REPORTING PERSONS

    Ryan Wilder

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) ¨

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    - 0 -

    6

    SHARED VOTING POWER

    6,100,000

    7

    SOLE DISPOSITIVE POWER

    - 0 -

    8

    SHARED DISPOSITIVE POWER

    6,100,000

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    6,100,000

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    9.9%

    12

    TYPE OF REPORTING PERSON

    IN, HC

             

     

    CUSIP No. 70271210013GPage 4 of 7 Pages

     

     

    Item 1(a). NAME OF ISSUER.
       
      The name of the issuer is Passage BIO, Inc. (the "Company").

     

    Item 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
       
     

    The Company's principal executive offices are located at One Commerce Square, 2005

    Market Street, 39th Floor, Philadelphia, PA 19103.

     

    Item 2(a). NAME OF PERSON FILING:
       
      This statement is filed by:

     

      (i)

    Vestal Point Capital, LP (the "Investment Manager"), a Delaware limited partnership, and the investment adviser to a certain fund and a managed account (the "Vestal Point Fund and Account"), with respect to the shares of Common Stock (as defined in Item 2(d) below) directly held by the Vestal Point Fund and Account; and

     

      (ii) Mr. Ryan Wilder ("Mr. Wilder"), the  Chief Investment Officer and Managing Partner of the Investment Manager and the Managing Member of Vestal Point Capital, LLC, the general partner of the Investment Manager, with respect to the shares of Common Stock directly held by the Vestal Point Fund and Account.

     

      The foregoing persons are hereinafter sometimes collectively referred to as the "Reporting Persons."
       
      The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the shares of Common Stock reported herein.  

     

    Item 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
       
      The address of the business office of each of the Reporting Persons is 632 Broadway, Suite 602, New York, NY 10012.

     

    Item 2(c). CITIZENSHIP:
       
      The Investment Manager is a Delaware limited partnership.  Mr. Wilder is a citizen of the United States.

     

    Item 2(d). TITLE OF CLASS OF SECURITIES:
       
      Common stock, par value $0.0001 per share (the "Common Stock").

     

    Item 2(e). CUSIP NUMBER:
       
      702712100

     

     

    CUSIP No. 70271210013GPage 5 of 7 Pages

     

    Item 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

     

      (a) ¨ Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
      (b) ¨ Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
      (c) ¨ Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
      (d) ¨ Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
      (e) x Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);
      (f) ¨

    Employee benefit plan or endowment fund in accordance with

    Rule 13d-1(b)(1)(ii)(F);

     

      (g) x

    Parent holding company or control person in accordance with

    Rule 13d-1(b)(1)(ii)(G);

      (h) ¨

    Savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     

      (i) ¨

    Church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);

     

      (j) ¨ Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J);
      (k) ¨ Group, in accordance with Rule 13d-1(b)(1)(ii)(K).

     

     

    If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please

    specify the type of institution: ______________________

     

    Item 4. OWNERSHIP.
       
      The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of the cover page for each of the Reporting Persons and is incorporated herein by reference.
       
      The percentages set forth herein are calculated based upon 61,767,286 shares of Common Stock outstanding as of August 5, 2024, as reported in the Company's Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2024, filed with the Securities and Exchange Commission on August 8, 2024.

     

    Item 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      Not applicable.

     

     

    CUSIP No. 70271210013GPage 6 of 7 Pages

     

    Item 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      See Item 2(a).  The Vestal Point Fund and Account have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the shares of Common Stock reported herein.  

     

    Item 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.

     

    Item 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.

     

    Item 9. NOTICE OF DISSOLUTION OF GROUP.
       
      Not applicable.

     

    Item 10. CERTIFICATION.
       
      Each of the Reporting Persons hereby makes the following certification:
       
      By signing below each Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 70271210013GPage 7 of 7 Pages

     

    SIGNATURES

    After reasonable inquiry and to the best of his or its knowledge and belief, each of the undersigned certify that the information set forth in this statement is true, complete and correct.

    DATED: November 14, 2024

     

     

    VESTAL POINT CAPITAL, LP
    By: VESTAL POINT CAPITAL, LLC, its general partner  
         
    By: /s/ Ryan Wilder  
    Name: Ryan Wilder  
    Title: Chief Investment Officer and Managing Partner  
         
         
    /s/ Ryan Wilder  
    Ryan Wilder  

     

     

    Get the next $PASG alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PASG

    DatePrice TargetRatingAnalyst
    11/29/2024$3.00 → $4.00Outperform
    Wedbush
    9/3/2024$7.00Buy
    Rodman & Renshaw
    3/8/2022Overweight → Neutral
    JP Morgan
    3/4/2022$29.00 → $24.00Outperform
    Raymond James
    1/19/2022$29.00 → $6.00Buy → Neutral
    Goldman
    7/1/2021$29.00Outperform
    Raymond James
    More analyst ratings

    $PASG
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights

      Interim data from Dose 1 PBFT02 demonstrated durable, elevated CSF PGRN and early evidence of reduction in plasma NfL levels, a disease progression biomarker, as compared to published natural history Enrolled first FTD-GRN patient to be treated with Dose 2 PBFT02, 50% lower than Dose 1 Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Extended cash runway into 1Q 2027 PHILADELPHIA, March 04, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative d

      3/4/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio to Participate in Upcoming Investor Conferences

      PHILADELPHIA, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced management will participate in the following upcoming investor conferences: TD Cowen 45th Annual Health Care ConferenceFormat: Management will participate in a presentation and investor meetingsDate: Wednesday, March 5, 2025Presentation Time: 9:10 a.m. ETLocation: Boston, MA Leerink Global Biopharma Conference Format: Management will participate in a presentation and investor meetingsDate: Wednesday, March 12, 2025Presentation Time: 8:00 a.m. ETLocation: Miami, FL A live web

      2/26/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates

      PBFT02 demonstrated durable, elevated CSF PGRN levels and early evidence of reduction in plasma NfL levels, a disease progression biomarker, compared to published natural history data Evaluating Dose 2, 50% lower than Dose 1, in subsequent FTD-GRN and FTD-C9orf72 patients to allow for dose exploration and support regulatory strategy Expect to report 12-month data from Dose 1 and interim safety and biomarker data from Dose 2 in 2H 2025; plan to seek regulatory feedback on FTD-GRN pivotal trial design in 1H 2026 Completed process development and scale-up of a high-productivity, suspension-based manufacturing process for PBFT02 Extended cash runway into 1Q 2027 by moving to outsourc

      1/10/25 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more

    $PASG
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Large owner Lynx1 Capital Management Lp bought $241,038 worth of shares (373,645 units at $0.65) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      12/31/24 4:05:36 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Lynx1 Capital Management Lp bought $146,665 worth of shares (259,998 units at $0.56) and bought $137,855 worth of shares (196,355 units at $0.70) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      11/27/24 6:11:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Passage Bio Inc.

      SC 13G - Passage BIO, Inc. (0001787297) (Subject)

      11/14/24 12:03:11 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Passage Bio Inc.

      SC 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 7:06:55 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Passage Bio Inc.

      SC 13G/A - Passage BIO, Inc. (0001787297) (Subject)

      8/9/24 5:15:23 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Financials

    Live finance-specific insights

    See more
    • Passage Bio Announces Promising Initial Data From Phase 1/2 Clinical Trial of PBFT02 in FTD-GRN and Updated Strategic Priorities

      Dose 1 of PBFT02 achieved supraphysiologic CSF progranulin levels in each of the first three treated patients at 30 days after treatmentElevated progranulin levels were sustained at up to six months post-treatmentDose 1 of PBFT02 was generally well-tolerated in patients who received an enhanced steroid regimen for immunosuppression Pipeline to focus on continued advancement of PBFT02 in FTD-GRN and explore PBFT02 in multiple additional adult neurodegenerative diseases Pursuing potential partnership opportunities for clinical-stage pediatric lysosomal storage disease programs including GM1 gangliosidosisManagement to host a webcast presentation to review interim FTD data today at 8:30 a.m. ET

      12/20/23 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Announces Promising Interim Clinical Data from First Eight Patients with GM1 Gangliosidosis in Imagine-1 Study

      Interim safety data up to 28 months showed Dose 1 and 2 of PBGM01 were well tolerated and had a favorable safety and immunological profileDose 2 resulted in substantial improvements in key CSF biomarkers and was able to achieve normal levels of CSF β-Gal activity and GM1 gangliosides, similar to healthy controlsDose 2 biomarker responses demonstrated durability up to 12 months after treatmentImagine-1 study participants showed initial evidence of improved survival relative to natural history dataTreated first patient at highest dose level, Dose 3, in July; initial safety and biomarker data from Dose 3 expected by mid-2024Management to host a conference call and webcast today at 8:30 a.m. ET

      8/7/23 7:00:12 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Recent Business Highlights

      Presented additional interim data at 19th Annual WORLDSymposium™ showing PBGM01 continued to demonstrate a biological effect in first six patients in Imagine-1 study for GM1 gangliosidosis; initial safety and biomarker data from Cohort 4 expected in mid-2023Planned expansion of Imagine-1 study to treat patients at a higher dose; expect to dose first patient in second half of 2023Plan to report initial safety and biomarker data from Cohort 1 of global upliFT-D trial for frontotemporal dementia in the second half of 2023Ended 2022 with strong cash position; cash runway into the first half of 2025Management to host conference call today at 8:30 a.m. ET PHILADELPHIA, March 06, 2023 (GLOBE NEW

      3/6/23 7:00:41 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Leadership Updates

    Live Leadership Updates

    See more
    • Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights

      Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from Cohort 1 FTD-GRN showed PBFT02 was generally well-tolerated and elevated CSF progranulin levels for up to 12 months following treatment Highlighted robust preclinical data supporting PBFT02 as a potential best-in-class progranulin-raising therapy in an oral presentation at ESGCT Execution backed by strong balance sheet, with cash runway to the end of Q2 2026 PHILADELPHIA, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines comp

      11/13/24 7:00:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Welcomes Tom Kassberg to Board of Directors

      PHILADELPHIA, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ:PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced the appointment of Tom Kassberg to the Board of Directors and his appointment to the Audit Committee. Mr. Kassberg is currently Chief Business Officer and Executive Vice President at Ultragenyx, a biopharmaceutical company committed to bringing novel therapies to patients for the treatment of serious rare and ultrarare genetic diseases. "We are pleased to welcome Tom Kassberg to the Passage Bio Board of Directors, where he will play an influential role in driving our mission

      9/10/24 7:52:00 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

      Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of PBGM01 was able to achieve healthy control levels of CSF β-Gal activity and GM1 gangliosides, with response durable up to 12 months Treated first patient at Dose 3 in Imagine-1 clinical trial in July 2023; initial safety and biomarker data from Dose 3 patients expected by mid-2024Expect to present initial safety and biomarker data from Cohort 1 in global Phase 1/2 upliFT-D trial of PBFT02 for the treatment frontotemporal dementia (FTD) with granulin mutations (GRN) in Q4 202

      8/7/23 7:15:54 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    SEC Filings

    See more
    • Amendment: SEC Form SCHEDULE 13D/A filed by Passage Bio Inc.

      SCHEDULE 13D/A - Passage BIO, Inc. (0001787297) (Subject)

      4/25/25 7:48:26 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEFA14A filed by Passage Bio Inc.

      DEFA14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:01:31 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form DEF 14A filed by Passage Bio Inc.

      DEF 14A - Passage BIO, Inc. (0001787297) (Filer)

      4/16/25 7:00:29 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Wedbush resumed coverage on Passage BIO with a new price target

      Wedbush resumed coverage of Passage BIO with a rating of Outperform and set a new price target of $4.00 from $3.00 previously

      11/29/24 7:25:55 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Rodman & Renshaw initiated coverage on Passage BIO with a new price target

      Rodman & Renshaw initiated coverage of Passage BIO with a rating of Buy and set a new price target of $7.00

      9/3/24 8:12:19 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Passage Bio downgraded by JP Morgan

      JP Morgan downgraded Passage Bio from Overweight to Neutral

      3/8/22 5:15:06 AM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PASG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Large owner Orbimed Advisors Llc sold $78,731 worth of shares (235,572 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/24/25 5:38:49 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Large owner Orbimed Advisors Llc sold $49,704 worth of shares (149,054 units at $0.33) (SEC Form 4)

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      4/17/25 6:10:47 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by CFO Borthwick Kathleen

      4 - Passage BIO, Inc. (0001787297) (Issuer)

      3/18/25 5:12:20 PM ET
      $PASG
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care